IDX719: Phase Ia started

Idenix began the Phase Ia portion of a U.S. Phase I trial of once-daily 5-100 mg IDX719. The Phase Ia portion will evaluate single doses of IDX719 in 48 healthy volunteers. The Phase Ib portion, which...